BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

BioNTech SE will release its financial results for the second quarter of 2025 on August 4, 2025, and will hold a conference call and webcast that day at 8:00 a.m. EDT to discuss these results and ...

BioNTech SE will announce its financial results for the first quarter of 2025 on May 5, 2025, and will hold a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss these results and ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other top-performing stocks on ...

CureVac N.V. is a Germany-based biopharmaceutical company focused on the development of messenger RNA (mRNA)-based medicines, including vaccines and therapeutics, with its shares previously listed on ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and ...

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m.